Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.
The conference has a lot of great sessions, including an untraditional keynote speaker, Dr. Hastings said.
HMA plus venetoclax was found to be effective and well tolerated in patients with AML who relapsed after HSCT.
Advertisement
The ORR was 64% in the frontline cohort and 46% in the relapsed or refractory cohort.
Monotherapy with pivekimab sunirine demonstrated activity in patients with relapsed or refractory CD123-positive AML.
These prospective results establish FLT3-ITD mutations as essential markers of MRD, the authors wrote.
The novel DuplexSeq AML-XP next-generation sequencing assay was highly accurate for detecting MRD in AML.
A significant number of patients receiving ivosidenib had reduced levels of voriconazole and posaconazole.
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
Benefit from treatment with quizartinib was accurately predicted by a “FLT3-like” gene expression signature in AML.
The percentage of KMT2A-altered cells decreased from 59.2% to 8.1% after treatment with JNJ-75276617.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Foretinib also showed potent activity against secondary mutations that drive resistance to quizartinib and gilteritinib.
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
The combined CR/CRi rate was 96% for the frontline cohort, compared with 27% for the relapsed or refractory cohort.
Researchers from St. Jude Children’s Research Hospital developed SJ3149, a selective and potent degrader of CK1α protein.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.